Gadobenate dimeglumine administration and nephrogenic systemic fibrosis: Is there a real risk in patients with impaired renal function?

Radiology

Volumn 276, Issue 3, 2015, Pages 741-747

  Nandwana, Sadhna B ^a   Moreno, Courtney C ^a   Osipow, Michael T ^a   Sekhar, Aarti ^a   Cox, Kelly L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM; GADOBENIC ACID; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ADULT; ARTICLE; CONTROLLED STUDY; DIALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HOSPITAL ADMISSION; HUMAN; IMAGE ANALYSIS; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEPHROGENIC SYSTEMIC FIBROSIS; OPERATION DURATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPLICATION; KIDNEY FAILURE; NEPHROGENIC FIBROSING DERMOPATHY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CONTRAST MEDIA; FEMALE; HUMANS; INCIDENCE; MALE; MEGLUMINE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; ORGANOMETALLIC COMPOUNDS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

EID: 84940851843     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2015142423     Document Type: Article

References (34)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356(9234):1000-1001.
2. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 2006;130(2):209-212.
3. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003;139(7):903-906.
4. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21(4):1104-1108.
5. Published correction appears in Nephrol Dial Transplant 2006;21(6):1745.
6. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56(1):21-26.
7. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56(4):710-712.
8. Martin DR, Krishnamoorthy SK, Kalb B, et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 2010;31(2):440-446.
9. Wermuth PJ, Jimenez SA. Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis. J Immunol 2012;189(1):318-327.
10. Piera-Velazquez S, Louneva N, Fertala J, Wermuth PJ, Del Galdo F, Jimenez SA. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Ann Rheum Dis 2010;69(11):2017-2023.
11. Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008;214(5):584-593.
12. U.S. Food and Drug Administration. FDA Drug Safety Communication: new warnings for using gadolinium based contrast agents in patients with kidney dysfunction. http://www.fda.gov/Drugs/DrugSafety/ucm223966.htm. Published 2010. Accessed July 15, 2014.
13. ACR Manual on Contrast Media. ACR Committee on Drugs and Contrast Media. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2013-Contrast-Media.pdf. Accessed July 15, 2014.
14. Wang Y, Alkasab TK, Narin O, et al. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 2011;260(1):105-111.
15. Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER 3rd, Semelka RC. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy-report from two U.S. universities. Radiology 2009;253(3):689-696.
16. Kalb B, Martin DR, Salman K, Sharma P, Votaw J, Larsen C. Kidney transplantation: structural and functional evaluation using MR Nephro-Urography. J Magn Reson Imaging 2008;28(4):805-822.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130(6):461-470.
18. US Food and Drug Administration Center for Drug Evaluation and Research. Transcript of Joint Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees meeting, December 8, 2009. http://www.fda.gov/downloads/Advisory-Committees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM197768.pdf. Accessed July 15, 2014.
19. Joffe P, Thomsen HS, Meusel M. Pharmaco-kinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5(7):491-502.
20. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol 2001;42(3):339-341.
21. Centers for Disease Control and Prevention (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents-St. Louis, Mo, 2002-2006. MMWR Morb Mortal Wkly Rep 2007;56(7):137-141.
22. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008;248(3):807-816.
23. Thomsen HS, Marckmann P, Logager VB. Update on nephrogenic systemic fibrosis. Magn Reson Imaging Clin N Am 2008;16(4):551-560, vii.
24. Bennett CL, Qureshi ZP, Sartor AO, et al. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J 2012;5(1):82-88.
25. Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis 2011;18(3):188-198.
26. Fretellier N, Idée JM, Dencausse A, et al. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol 2011;46(5):292-300.
27. Ersoy H, Rybicki FJ. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging 2007; 26(5):1190-1197.
28. Heverhagen JT, Krombach GA, Gizewski E. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis. Rofo 2014; 186(7):661-669.
29. Fernandes S, Carrelha AS, Marques Pinto G, Nolasco F, Barroso E, Cardoso J. Skin disease in liver and kidney transplant recipients referred to the department of dermatology and venereology [in Portuguese]. Acta Med Port 2013;26(5):555-563.
30. Savoia P, Stroppiana E, Cavaliere G, et al. Skin cancers and other cutaneous diseases in renal transplant recipients: a single Italian center observational study. Eur J Dermatol 2011;21(2):242-247.
31. Zamanian A, Mahjub H, Mehralian A. Skin diseases in kidney transplant recipients. Urol J 2006;3(4):230-233.
32. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008;43(2):141-144.
33. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007;56(10):3433-3441.
34. Hope TA, Herfkens RJ, Denianke KS, LeBoit PE, Hung YY, Weil E. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. Invest Radiol 2009;44(3):135-139.